LY-2624587

LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research[1][2].

Product Specifications

CAS Number

[2125546-89-4]

UNSPSC

12352100

Target

Akt; Apoptosis; CXCR; p38 MAPK

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; PI3K/Akt/mTOR

Field of Research

Cancer

References & Citations

[1]Peng SB, et al. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS One. 2016 Mar 8;11 (3) :e0150585. |[2]Cho BS, et al. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Korean J Intern Med. 2017 Mar;32 (2) :248-257.